litlas
Log inCreate account

Dongsheng Tu

Active 1987–2025

127
Papers
35,595
Citations
80
h-index
117
i10-index

Citations

Citations per year for Dongsheng Tu1974: 1 citations1988: 5 citations1989: 2 citations1990: 2 citations1991: 4 citations1992: 2 citations1993: 2 citations1994: 1 citations1995: 4 citations1996: 6 citations1997: 8 citations1998: 8 citations1999: 17 citations2000: 22 citations2001: 16 citations2002: 16 citations2003: 22 citations2004: 27 citations2005: 98 citations2006: 240 citations2007: 312 citations2008: 297 citations2009: 354 citations2010: 426 citations2011: 369 citations2012: 349 citations2013: 354 citations2014: 315 citations2015: 281 citations2016: 234 citations2017: 266 citations2018: 206 citations2019: 641 citations2020: 653 citations2021: 625 citations2022: 476 citations2023: 369 citations2024: 654 citations2025: 356 citations2026: 7 citations1975–1987: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,161 citing papers, 26.5% of this breakdownChina: 850 citing papers, 7.1% of this breakdownUnited Kingdom: 826 citing papers, 6.9% of this breakdownItaly: 732 citing papers, 6.1% of this breakdownCanada: 708 citing papers, 5.9% of this breakdownGermany: 626 citing papers, 5.3% of this breakdownFrance: 457 citing papers, 3.8% of this breakdownSpain: 434 citing papers, 3.7% of this breakdownJapan: 370 citing papers, 3.1% of this breakdownAustralia: 343 citing papers, 2.9% of this breakdownNetherlands: 330 citing papers, 2.8% of this breakdownBelgium: 250 citing papers, 2.1% of this breakdown
0%26.5%Other 23.8%

Institutions

Fields

  • Medicine63.6%
  • Biochemistry, Genetics and Molecular Biology23.4%
  • Mathematics2.5%
  • Computer Science2.4%
  • Immunology and Microbiology1.8%
  • Economics, Econometrics and Finance0.9%
  • Other5.4%

Topics

  • Colorectal Cancer Treatments and Studies5.6%
  • Lung Cancer Treatments and Mutations5.3%
  • HER2/EGFR in Cancer Research3.2%
  • Cancer Genomics and Diagnostics3.1%
  • Breast Cancer Treatment Studies3.1%
  • Cancer Immunotherapy and Biomarkers2.8%
  • Other76.9%

Coauthors

All papers

Open in search
  1. Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer

    Authors: Eric X. Chen, Derek J. Jonker, Jonathan M. Loree, Hagen F. Kennecke, Scott Berry, Félix Couture, Chaudhary E. Ahmad, John R. Goffin, Petr Kavan, Mohammed Harb, Bruce Colwell, Setareh Samimi, Benoît Samson, Tahir Abbas, Nathalie Aucoin, Francine Aubin, Sheryl Koski, Alice C. Wei, Nadine M Magoski, Dongsheng Tu, Chris J. O’Callaghan - JAMA Oncology 2020 cited by 398

  2. K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

    Authors: Christos S. Karapetis, Shirin Khambata‐Ford, Derek J. Jonker, Chris J. O’Callaghan, Dongsheng Tu, Niall C. Tebbutt, R. J. Simes, Haji Chalchal, Jeremy Shapiro, Sonia Robitaille, Timothy Price, Lois E. Shepherd, Heather‐Jane Au, Christiane Langer, Malcolm J. Moore, John Zalcberg - New England Journal of Medicine 2008 cited by 3,597

  3. Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer

    Authors: Marie Plante, Janice S. Kwon, Sarah E. Ferguson, Vanessa Samouëlian, Gwénaël Ferron, Amandine Maulard, Cor D. de Kroon, Willemien J. van Driel, John Tidy, Karin Williamson, Sven� Mahner, Stefan Kommoss, Frédéric Goffin, Karl Tamussino, Brynhildur Eyjólfsdóttir, Jae‐Weon Kim, Noreen Gleeson, Lori A. Brotto, Dongsheng Tu, Lois E. Shepherd - New England Journal of Medicine 2024 cited by 252

  4. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

    Authors: Richard J. Gray, Rosie Bradley, Jeremy Braybrooke, Zulian Liu, Richárd Pető, Lucy Davies, David Dodwell, Paul McGale, Hongchao Pan, Carolyn Taylor, William E. Barlow, Judith M. Bliss, Paolo Bruzzi, David Cameron, George Fountzilas, Sibylle Loibl, John R. Mackey, Miguel Martín, Lucia Del Mastro, Volker Möbus, Valentina Nekljudova, Sabino De Placido, Sandra M. Swain, Michael Untch, Kathleen I. Pritchard, Jonas Bergh, Larry Norton, Clare Boddington, Julie Ann Burrett, Mike Clarke, Christina Davies, Frances Duane, Vaughan Evans, Lucy Gettins, Jon Godwin, Robert K. Hills, Sam James, Hui Liu, Elizabeth MacKinnon, Gurdeep Mannu, Theresa McHugh, Philip Morris, Simon Read, Yaochen Wang, Zhe Wang, Peter A. Fasching, Nadia Harbeck, Pascal Piedbois, Michael Gnant, Guenther G. Steger, Angelo Di Leo, Stella Dolci, Prue Francis, Denis Larsimont, J.-M. Nogaret, C. Philippson, Martine Piccart, Sabine C. Linn, Petronella G.M. Peer, Vivianne C. G. Tjan‐Heijnen, S.B. Vliek, John R. Mackey, Dennis Slamon, John M.S. Bartlett, Vivien Bramwell, Bingshu E. Chen, Stephen Chia, Karen A. Gelmon, Paul E. Goss, Mark N. Levine, Wendy R. Parulekar, Joseph L. Pater, Eileen Rakovitch, Lois E. Shepherd, Dongsheng Tu, Timothy J. Whelan, Donald A. Berry, Gloria Broadwater, Constance Cirrincione, Hyman B. Muss, Raymond L. Weiss, Yi Shan, Yong fu Shao, Xiang Wang, Binghe Xu, Dongbing Zhao, Harry Bartelink, Nina Bijker, Jan Bogaerts, Fátima Cardoso, Tanja Čufer, Jean‐Pierre Julien, Philip Poortmans, Emiel J. Rutgers, Cornelis J.�H. van de Velde, Eva Carrasco, Miguel Ángel Seguí, Jens‐Uwe Blohmer, Serban Dan Costa, Bernd Gerber and 67 more - The Lancet 2019 cited by 394

  5. The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma

    Authors: Daniel J. Renouf, Jonathan M. Loree, Jennifer J. Knox, James T. Topham, Petr Kavan, Derek J. Jonker, Stephen Welch, Félix Couture, Frédéric Lemay, Mustapha Tehfé, Mohammed Harb, Nathalie Aucoin, Yoo‐Joung Ko, Patricia A. Tang, Ravi Ramjeesingh, Brandon M. Meyers, Christina Kim, Pan Du, Shidong Jia, David F. Schaeffer, Sharlene Gill, Dongsheng Tu, Chris J. O’Callaghan - Nature Communications 2022 cited by 139

  6. Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies

    Authors: John Hilton, Karen A. Gelmon, Philippe L. Bédard, Dongsheng Tu, Hong Xu, Anna V. Tinker, Rachel Goodwin, Scott A. Laurie, Derek J. Jonker, Aaron R. Hansen, Zachary Veitch, Daniel J. Renouf, Linda Hagerman, Hongbo Lui, Bingshu E. Chen, Deb Kellar, Irene Li, Sung‐Eun Lee, Takako Kono, Brian Yu Chieh Cheng, Damian Yap, Daniel Lai, Sean Beatty, John Soong, Kathleen I. Pritchard, Isabel Soria‐Bretones, Eric X. Chen, Harriet Feilotter, Moira Rushton, Lesley Seymour, Samuel Aparício, David W. Cescon - Nature Communications 2022 cited by 145

  7. Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

    Authors: Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu, Eng Huat Tan, Vera Hirsh, Sumitra Thongprasert, Daniel de Castro, Savitree Maoleekoonpiroj, Michael Smylie, Renato Martins, Maximiliano Van Kooten, Mircea Dediu, B. Findlay, Dongsheng Tu, D. Johnston, Andrea Bezjak, Gary M. Clark, P. Santabárbara, Lesley Seymour - New England Journal of Medicine 2005 cited by 5,451

  8. Cetuximab for the Treatment of Colorectal Cancer

    Authors: Derek J. Jonker, Chris J. O’Callaghan, Christos S. Karapetis, John Zalcberg, Dongsheng Tu, Heather-Jane Au, Scott Berry, Marianne Krahn, Timothy Price, R. J. Simes, Niall C. Tebbutt, Guy van Hazel, Rafal Wierzbicki, Christiane Langer, Malcolm J. Moore - New England Journal of Medicine 2007 cited by 1,806

  9. Evaluating the Time Toxicity of Cancer Treatment in the CCTG CO.17 Trial

    Authors: Arjun Gupta, Christopher J. O’Callaghan, Liting Zhu, Derek J. Jonker, Ralph Wong, Bruce Colwell, Malcolm J. Moore, Christos S. Karapetis, Niall C. Tebbutt, Jeremy Shapiro, Dongsheng Tu, Christopher M. Booth - JCO Oncology Practice 2023 cited by 69

  10. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

    Authors: Paul E. Goss, James N. Ingle, Kathleen I. Pritchard, Nicholas J. Robert, Hyman B. Muss, Julie R. Gralow, Karen A. Gelmon, Timothy J. Whelan, Kathrin Strasser‐Weippl, S. Rubin, Keren Sturtz, Antonio C. Wolff, Eric P. Winer, Clifford A. Hudis, Alison Stopeck, J. Thaddeus Beck, Judith S. Kaur, Kate Whelan, Dongsheng Tu, Wendy R. Parulekar - New England Journal of Medicine 2016 cited by 648

  11. Exemestane for Breast-Cancer Prevention in Postmenopausal Women

    Authors: Paul E. Goss, James N. Ingle, José E. Alés‐Martínez, Angela M. Cheung, Rowan T. Chlebowski, Jean Wactawski‐Wende, Anne McTiernan, John A. Robbins, Karen Johnson, Lisa W. Martin, Eric Winquist, Gloria E. Sarto, Judy E. Garber, Carol J. Fabian, Pascal Pujol, Elizabeth Maunsell, Patricia Farmer, Karen A. Gelmon, Dongsheng Tu, Harriet Richardson - New England Journal of Medicine 2011 cited by 961

  12. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial

    Authors: Tingyan Shi, Jianqing Zhu, Yanling Feng, Dongsheng Tu, Yuqin Zhang, Zhang Ping, Huixun Jia, Xiao Huang, Yunlang Cai, Sheng Yin, Rong Jiang, Wenjuan Tian, Wen Gao, Jihong Liu, Huijuan Yang, Xi Cheng, Rongyu Zang - The Lancet Oncology 2021 cited by 227

  13. Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer

    Authors: Eric X. Chen, Jonathan M. Loree, Emma Titmuss, Derek J. Jonker, Hagen F. Kennecke, Scott Berry, Félix Couture, Chaudharry E. Ahmad, John R. Goffin, Petr Kavan, Mohammed Harb, Bruce Colwell, Setareh Samimi, Benoît Samson, Tahir Abbas, Nathalie Aucoin, Francine Aubin, Sheryl Koski, Alice C. Wei, Dongsheng Tu, Chris J. O’Callaghan - JAMA Network Open 2023 cited by 64

  14. Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial

    Authors: Derek J. Jonker, Louise Nott, Takayuki Yoshino, Sharlene Gill, Jeremy Shapiro, Atsushi Ohtsu, John Zalcberg, Michael M. Vickers, Alice C. Wei, Yuan Gao, Niall C. Tebbutt, Ben Markman, Timothy Price, Taito Esaki, Sheryl Koski, Matthew Hitron, Wěi Li, Youzhi Li, Nadine M Magoski, Chiang J. Li, John Simes, Dongsheng Tu, Christopher J. O’Callaghan - ˜The œLancet. Gastroenterology & hepatology 2018 cited by 168

  15. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial

    Authors: Quincy S. Chu, Federica Perrone, Laurent Greillier, Wei Tu, Maria Carmela Piccirillo, Federica Grosso, Giuseppe Lo Russo, Marie Florescu, Manlio Mencoboni, Alessandro Morabito, Fabiana Letizia Cecere, Giovanni Luca Ceresoli, David E. Dawe, Paolo Andrea Zucali, Maria Pagano, John R. Goffin, Myriam Locatelli Sanchez, Cesare Gridelli, Gérard Zalcman, Xavier Quantin, Virginie Westeel, Piera Gargiulo, Sara Delfanti, Dongsheng Tu, Christopher W. Lee, Natasha B. Leighl, Joana Sederias, Pamela Brown-Walker, Yiwen Luo, Sylvie Lantuéjoul, Ming‐Sound Tsao, Arnaud Scherpereel, Penelope A. Bradbury, Scott A. Laurie, Lesley Seymour - The Lancet 2023 cited by 101

  16. Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression

    Authors: Maggie C.U. Cheang, Miguel Martín, Torsten O. Nielsen, Aleix Prat, David Voduc, Álvaro Rodríguez-Lescure, Amparo Ruı́z, Stephen Chia, Lois E. Shepherd, Manuel Ruíz‐Borrego, Lourdes Calvo, Emilio Alba, Eva Carrasco, Rosalía Caballero, Dongsheng Tu, Kathleen I. Pritchard, Mark N. Levine, Vivien Bramwell, Joel S. Parker, Philip S. Bernard, Matthew J. Ellis, Charles M. Perou, Angelo Di Leo, Lisa A. Carey - The Oncologist 2015 cited by 198

  17. Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti–Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer

    Authors: James T. Topham, Chris J. O’Callaghan, Harriet Feilotter, Hagen F. Kennecke, Young S. Lee, Weimin Li, Kimberly C. Banks, Katie Quinn, Daniel J. Renouf, Derek J. Jonker, Dongsheng Tu, Eric X. Chen, Jonathan M. Loree - Journal of Clinical Oncology 2022 cited by 67

  18. Morphine, Gabapentin, or Their Combination for Neuropathic Pain

    Authors: Ian Gilron, Joan M. Bailey, Dongsheng Tu, Ronald R. Holden, Donald F. Weaver, Robyn L. Houlden - New England Journal of Medicine 2005 cited by 1,088

  19. Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

    Authors: Wendy De Roock, Derek J. Jonker, Federica Di Nicolantonio, Andrea Sartore‐Bianchi, Dongsheng Tu, Salvatore Siena, Simona Lamba, Sabrina Arena, Milo Frattini, Hubert Piessevaux, Eric Van Cutsem, Chris J. O’Callaghan, Shirin Khambata‐Ford, John Zalcberg, John Simes, Christos S. Karapetis, Alberto Bardelli, Sabine Tejpar - JAMA 2010 cited by 747

  20. The Jackknife and Bootstrap

    Authors: Jun Shao, Dongsheng Tu - Springer series in statistics 1995 cited by 1,994

  21. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17

    Authors: Stephanie Yasmin Brule, Derek J. Jonker, Christos S. Karapetis, Chris J. O’Callaghan, Malcolm J. Moore, Ralph Wong, Niall C. Tebbutt, Craig Underhill, Desmond Yip, John Zalcberg, Dongsheng Tu, Rachel Goodwin - European Journal of Cancer 2015 cited by 337

  22. Phase II study of PX-866 in recurrent glioblastoma

    Authors: Marshall Pitz, Elizabeth A. Eisenhauer, Mary MacNeil, Brian Thiessen, Jacob C. Easaw, David R. Macdonald, David D. Eisenstat, Ankineedu Saranya Kakumanu, Muhammad Salim, Haji Chalchal, Jeremy A. Squire, Ming‐Sound Tsao, Suzanne Kamel‐Reid, Shantanu Banerji, Dongsheng Tu, Jean Powers, Diana F. Hausman, Warren Mason - Neuro-Oncology 2015 cited by 119

  23. Quality of life as a prognostic indicator of survival: A pooled analysis of individual patient data from canadian cancer trials group clinical trials

    Authors: Divine Ediebah, Chantal Quinten, Corneel Coens, Jolie Ringash, Janet Dancey, Efstathios Zikos, Carolyn Gotay, Michael Brundage, Dongsheng Tu, Hans‐Henning Flechtner, Eva Greimel, Bryce B. Reeve, Martin Taphoorn, Jaap C. Reijneveld, Linda Dirven, Andrew Bottomley - Cancer 2018 cited by 99

  24. A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen

    Authors: Stephen Chia, Vivien Bramwell, Dongsheng Tu, Lois E. Shepherd, Shan Jiang, Tammi L. Vickery, Elaine R. Mardis, Samuel Leung, Karen Ung, Kathleen I. Pritchard, Joel S. Parker, Philip S. Bernard, Charles M. Perou, Matthew J. Ellis, Torsten O. Nielsen - Clinical Cancer Research 2012 cited by 310